WuXi Biologics (Cayman) Inc
HKEX:2269
Intrinsic Value
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. [ Read More ]
The intrinsic value of one
WuXi Biologics (Cayman) Inc
stock under the Base Case scenario is
30.69
HKD.
Compared to the current market price of 12.9 HKD,
WuXi Biologics (Cayman) Inc
is
Undervalued by 58%.
WuXi Biologics (Cayman) Inc's market capitalization is 54.9B HKD.
WuXi Biologics (Cayman) Inc stock price is 12.9 HKD.
WuXi Biologics (Cayman) Inc stock price (12.9 HKD) is 58% less than its Intrinsic Value (30.69 HKD).
WuXi Biologics (Cayman) Inc stock (11.39 HKD) is 12% less than its price (12.9 HKD). Open DCF Valuation
WuXi Biologics (Cayman) Inc stock price (12.9 HKD) is 74% less than its Relative Value (49.99 HKD). Open Relative Valuation
WuXi Biologics (Cayman) Inc has upside potential of 190% compared to the average analyst price target.
Open Wall St Estimates
WuXi Biologics (Cayman) Inc has positive three-year average ROIC (Return on Invested Capital): 10%. The company is efficient at using invested capital to generate operating income.
WuXi Biologics (Cayman) Inc's ROIC (Return on Invested Capital) has decreased in the last 3 years from 9% to 9%.
WuXi Biologics (Cayman) Inc's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
WuXi Biologics (Cayman) Inc's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
WuXi Biologics (Cayman) Inc's ROE (Return on Equity) has decreased in the last 3 years from 10% to 9%.
WuXi Biologics (Cayman) Inc's Revenue has grown by 12% over the past 12 months.
WuXi Biologics (Cayman) Inc has positive three-year average ROE (Return on Equity): 12%. The company is efficient at transforming stockholders' equity into net income.
WuXi Biologics (Cayman) Inc's Revenue is forecast to grow at a rate of 13% per year over the next 3 years.
WuXi Biologics (Cayman) Inc has positive Net Income for the last twelve months.
WuXi Biologics (Cayman) Inc has positive Operating Income for the last twelve months.
WuXi Biologics (Cayman) Inc has positive Gross Profit for the last twelve months.
WuXi Biologics (Cayman) Inc's Revenue has been growing by an exceptional 45% per year for the last 3 years.
WuXi Biologics (Cayman) Inc's short-term assets (21B CNY) exceed its short-term liabilties (8B CNY).
WuXi Biologics (Cayman) Inc has negative Net Debt. This means that the company has more cash and short-term investments (11B CNY) than debt (4B CNY).
WuXi Biologics (Cayman) Inc has positive Free Cash Flow for the last twelve months.
WuXi Biologics (Cayman) Inc's long-term assets (57B CNY) exceed its long-term liabilties (16B CNY).
WuXi Biologics (Cayman) Inc's D/E (Debt to Equity) is very low and is equal to 0.1.
WuXi Biologics (Cayman) Inc's Altman Z-Score is very high and is equal to 6.26.
WuXi Biologics (Cayman) Inc earns more than enough operating income (4B CNY) to safely cover interest payments on its debt (174m CNY).
Valuation Backtest
WuXi Biologics (Cayman) Inc
Run backtest to discover the historical profit from buying and selling
WuXi Biologics (Cayman) Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
WuXi Biologics (Cayman) Inc
Balance Sheet Decomposition
WuXi Biologics (Cayman) Inc
| Current Assets | 21.2B |
| Cash & Short-Term Investments | 11.2B |
| Receivables | 6.8B |
| Other Current Assets | 3.1B |
| Non-Current Assets | 35.4B |
| Long-Term Investments | 2.9B |
| PP&E | 29.9B |
| Intangibles | 2B |
| Other Non-Current Assets | 462m |
| Current Liabilities | 7.6B |
| Accounts Payable | 2.8B |
| Other Current Liabilities | 4.9B |
| Non-Current Liabilities | 8.6B |
| Long-Term Debt | 3.8B |
| Other Non-Current Liabilities | 4.8B |
Earnings Waterfall
WuXi Biologics (Cayman) Inc
|
Revenue
|
17B
CNY
|
|
Cost of Revenue
|
-10.2B
CNY
|
|
Gross Profit
|
6.8B
CNY
|
|
Operating Expenses
|
-2.4B
CNY
|
|
Operating Income
|
4.4B
CNY
|
|
Other Expenses
|
-1B
CNY
|
|
Net Income
|
3.4B
CNY
|
Free Cash Flow Analysis
WuXi Biologics (Cayman) Inc
Profitability Score
Profitability Due Diligence
WuXi Biologics (Cayman) Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
WuXi Biologics (Cayman) Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
WuXi Biologics (Cayman) Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Score
WuXi Biologics (Cayman) Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
WuXi Biologics (Cayman) Inc
According to Wall Street analysts, the average 1-year price target for
WuXi Biologics (Cayman) Inc
is 37.47 HKD
with a low forecast of 12.12 HKD and a high forecast of 73.5 HKD.
Shareholder Return
Price
WuXi Biologics (Cayman) Inc
| Average Annual Return | 48.01% |
| Standard Deviation of Annual Returns | 109.03% |
| Max Drawdown | -91% |
| Market Capitalization | 54.9B HKD |
| Shares Outstanding | 4 259 140 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
WuXi Biologics (Cayman) Inc
Country
Industry
Market Cap
Dividend Yield
Description
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. The company is headquartered in Wuxi, Jiangsu. The company went IPO on 2017-06-13. The firm's technology platforms include WuXiBody TM bispecific antibody technology platform and antibody drug conjugates (ADC) technology platform. The company has brought in several new projects into its pipeline. The firm has a vaccine manufacturing facility and produces vaccines for customers to supply the global market. The firm conducts its businesses within the China market and to overseas markets, such as North America, Europe and other markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
WuXi Biologics (Cayman) Inc
stock under the Base Case scenario is
30.69
HKD.
Compared to the current market price of 12.9 HKD,
WuXi Biologics (Cayman) Inc
is
Undervalued by 58%.
You don't have any saved screeners yet
